|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7534866B2
(en)
*
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
WO2002026265A2
(en)
|
2000-09-29 |
2002-04-04 |
Schering Corporation |
Pegylated interleukin-10
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CA2599734C
(en)
|
2005-03-03 |
2014-01-28 |
Immunomedics, Inc. |
Humanized l243 antibodies
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
EP1874824A4
(en)
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
JP2010516675A
(ja)
*
|
2007-01-17 |
2010-05-20 |
イミューノメディクス、インコーポレイテッド |
治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
|
|
AU2008275911A1
(en)
*
|
2007-07-19 |
2009-01-22 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
Self- anchoring MEMS intrafascicular neural electrode
|
|
CN103298935A
(zh)
*
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
CA2734265C
(en)
*
|
2008-08-20 |
2017-12-19 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
JP5888980B2
(ja)
|
2008-12-17 |
2016-03-22 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
|
|
SI2393828T1
(sl)
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
US8680050B2
(en)
*
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US20110046060A1
(en)
*
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
AU2010258898B8
(en)
|
2009-06-08 |
2015-02-05 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
CA2770351C
(en)
*
|
2009-08-31 |
2019-04-23 |
Ibc Pharmaceuticals, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
|
|
WO2011025904A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
WO2011056721A2
(en)
*
|
2009-11-05 |
2011-05-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
CA2782398C
(en)
*
|
2009-12-09 |
2017-09-26 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
EP2509629A4
(en)
*
|
2009-12-09 |
2013-06-26 |
Ibc Pharmaceuticals Inc |
DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
EP2635300A4
(en)
*
|
2010-11-03 |
2014-04-02 |
Ibc Pharmaceuticals Inc |
DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
|
|
US9140698B2
(en)
|
2011-04-06 |
2015-09-22 |
The Board Of Regents Of The University Of Texas System |
Modulating bacterial MAM polypeptides in pathogenic disease
|
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
CA2855566A1
(en)
|
2011-12-02 |
2013-06-06 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
ES2672974T3
(es)
|
2012-06-01 |
2018-06-19 |
Ibc Pharmaceuticals, Inc. |
Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
KR101358330B1
(ko)
|
2012-09-26 |
2014-02-12 |
현대모비스 주식회사 |
차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법
|
|
AU2013360335B2
(en)
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US9789156B2
(en)
|
2013-03-11 |
2017-10-17 |
Dana-Farber Cancer Institute, Inc. |
Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
|
|
AU2014254019B2
(en)
|
2013-04-18 |
2018-09-27 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
MX2016005915A
(es)
|
2013-11-11 |
2016-12-16 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
KR20160102210A
(ko)
|
2013-12-27 |
2016-08-29 |
노버스 인터내쇼날 인코포레이티드 |
에톡시화 계면활성제
|
|
US10605810B2
(en)
*
|
2013-12-30 |
2020-03-31 |
University-Industry Cooperation Group Of Kyung Hee University |
Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
|
|
EP3107577B1
(en)
|
2014-02-21 |
2024-03-20 |
IBC Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
CA2961774C
(en)
|
2014-10-07 |
2023-05-23 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
AU2015333827A1
(en)
|
2014-10-14 |
2017-04-20 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
KR20170125839A
(ko)
*
|
2015-03-11 |
2017-11-15 |
넥타르 테라퓨틱스 |
Ｉｌ-7 부분 및 중합체의 접합체
|
|
US9797907B2
(en)
|
2015-04-22 |
2017-10-24 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
US9687547B2
(en)
|
2015-05-28 |
2017-06-27 |
Immunomedics, Inc. |
T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
|
|
AU2016268403A1
(en)
|
2015-05-28 |
2017-12-07 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
US12158399B2
(en)
|
2016-08-05 |
2024-12-03 |
Duke University |
CaMKK2 inhibitor compositions and methods of using the same
|
|
WO2018102743A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN107118269B
(zh)
*
|
2017-06-05 |
2020-12-01 |
北京交通大学 |
一种重组人il-24蛋白的peg修饰方法
|
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
|
CN112004826B
(zh)
|
2018-02-05 |
2024-06-14 |
自由大学基金会 |
反向激动性抗us28抗体
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
JP7763589B2
(ja)
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|
|
WO2019227022A1
(en)
|
2018-05-25 |
2019-11-28 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
US12428626B2
(en)
|
2018-11-20 |
2025-09-30 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
US12410241B2
(en)
|
2019-07-26 |
2025-09-09 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus D68
|
|
AU2021220847A1
(en)
|
2020-02-11 |
2022-09-01 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
|
|
DK4045533T5
(da)
|
2020-03-26 |
2024-07-29 |
Univ Vanderbilt |
Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|